

This article was downloaded by:

On: 22 January 2011

Access details: *Access Details: Free Access*

Publisher *Taylor & Francis*

Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK



Journal of Asian Natural Products Research

Publication details, including instructions for authors and subscription information:

<http://www.informaworld.com/smpp/title~content=t713454007>

A New Triterpenoid from *Stelmatocrypton khasianum*

Qing-Ying Zhang^a; Yu-Ying Zhao; Tie-Ming Cheng^a; Yu-Xin Cui^a; Xue-Hui Liu^a

^a School of Pharmaceutical Sciences, Beijing Medical University, Beijing, China

To cite this Article Zhang, Qing-Ying , Zhao, Yu-Ying , Cheng, Tie-Ming , Cui, Yu-Xin and Liu, Xue-Hui(2009) 'A New Triterpenoid from *Stelmatocrypton khasianum*', Journal of Asian Natural Products Research, 2: 2, 81 – 86

To link to this Article: DOI: 10.1080/10286020008039896

URL: <http://dx.doi.org/10.1080/10286020008039896>

PLEASE SCROLL DOWN FOR ARTICLE

Full terms and conditions of use: <http://www.informaworld.com/terms-and-conditions-of-access.pdf>

This article may be used for research, teaching and private study purposes. Any substantial or systematic reproduction, re-distribution, re-selling, loan or sub-licensing, systematic supply or distribution in any form to anyone is expressly forbidden.

The publisher does not give any warranty express or implied or make any representation that the contents will be complete or accurate or up to date. The accuracy of any instructions, formulae and drug doses should be independently verified with primary sources. The publisher shall not be liable for any loss, actions, claims, proceedings, demand or costs or damages whatsoever or howsoever caused arising directly or indirectly in connection with or arising out of the use of this material.

A NEW TRITERPENOID FROM *STEMATOCRYPTON KHASIANUM*

QING-YING ZHANG, YU-YING ZHAO*, TIE-MING CHENG,
YU-XIN CUI and XUE-HUI LIU

*School of Pharmaceutical Sciences, Beijing Medical University,
Beijing 100083, China*

(Received 12 April 1999; Revised 30 April 1999; In final form 21 June 1999)

A new triterpenoid, 2α -, 3β -, 19α -trihydroxy-urs-12-ene-24,28-dioic acid (**1**), along with two known compounds, 3β -acetoxy-urs-12-ene-11-one (**2**) and vomifoliol (**3**), was isolated from stems of *Stemmatocrypton khasianum* for the first time. Their structures were elucidated on the basis of chemical and spectroscopic methods.

Keywords: *Stemmatocrypton khasianum*; Asclepiadaceae;
 2α -, 3β -, 19α -Trihydroxy-urs-12-ene-24,28-dioic acid

INTRODUCTION

Stemmatocrypton khasianum (Benth.) Bail.(Asclepiadaceae) is distributed in India, and Yunnan, Guizhou and Sichuan Provinces of China. It is used in Chinese folk medicine for the treatment of cold, tracheitis, stomachache and rheumatic ache. However, only one compound, 4-methoxy salyclic aldehyde, was obtained from its roots by steam distillation [1]. We have taken this plant for systematic phytochemical investigations and some compounds have been isolated. This paper reports the isolation and structural elucidation of a new triterpenoid, 2α -, 3β -, 19α -trihydroxy-urs-12-ene-24,28-dioic acid (**1**), together with two known compounds, 3β -acetoxy-urs-12-ene-11-one (**2**) and vomifoliol (**3**).

* Corresponding author. Tel.: (010) 62091592. Fax: (010) 62015584.
E-mail: nmechem@mail.bjmu.edu.cn.

RESULTS AND DISCUSSION

Ninety-five percent ethanol extracts of stems of *S. khasianum* were suspended in H₂O and then extracted with petroleum ether, ethyl ether and *n*-BuOH, respectively. The ethyl ether soluble part was separated by usual chromatographic methods to afford compound **1**.

Compound **1** was obtained as a white powder. A positive Libermann–Buchard reaction and its NMR spectra suggested it to be a triterpenoid. The ¹H-NMR spectrum showed signals for six methyl groups at δ 1.05, 1.11, 1.39, 1.65, 1.68 (each 3H, s) and 1.06 (3H, d, $J = 8.5$ Hz), two carbinol protons at δ 3.35 (1H, d, $J = 8.0$ Hz) and 4.69 (1H, m), and one trisubstituted olefinic proton at δ 5.51 (1H, brs). The ¹³C-NMR spectrum revealed the presence of three oxygenated carbons at δ 68.2, 72.3 and 83.7, a pair of olefinic carbons at δ 127.6 and 139.5, and two carbonyl carbons at δ 180.3 and 180.5. The DEPT spectrum showed the presence of nine quaternary carbons (C), seven tertiary carbons (CH), eight secondary carbons (CH₂) and six primary carbons (CH₃). The FAB-MS exhibited quasimolecular ion peaks at m/z 519 ($M^+ + 1$) and 541 ($M^+ + Na$), corresponding to a molecular formula of C₃₀H₄₆O₇. The above evidences suggested that compound **1** was a trihydroxy-substituted urs-12-ene type triterpenoid with two carboxylic groups, and one of the three hydroxyl groups was linked at 19 or 20 position because there was only one doublet methyl group. The presence of a singlet at δ 2.96 attributed to H-18 in the ¹H-NMR spectrum indicated that the hydroxyl group was located at 19 position which was further confirmed by the absence of cross peaks of H-18 in the ¹H–¹H COSY spectrum. In the ¹H-NMR spectrum, two one proton signals for carbinol protons at δ 3.35 and 4.69 were ascribed to H-3 and H-2, respectively, on the basis of biogenetic analogy and analysis of NMR spectra, and the large coupling constant of $J_{2,3}$ (8.0 Hz) indicated that 2-OH and 3-OH were α - and β -orientated, respectively. The HMBC spectrum showed strong cross peaks between δ 180.3 (COOH) and δ 3.34 (H-3), 1.18 (H-5) and δ 1.68 (CH₃), and δ 180.5 (COOH) and 2.96 (H-18), suggesting that the carboxyl carbon at δ 180.3 be linked at 4 position and the carboxyl carbon at δ 180.5 be linked at 17 position (Fig. 1). Therefore, the structure of compound **1** must be either 2 α -,3 β -,19 α -trihydroxy-urs-12-ene-23,28-dioic acid or 2 α -,3 β -,19 α -trihydroxy-urs-12-ene-24,28-dioic acid. However, the ¹³C-NMR data of compound **1** were not in agreement with the published data [2] of 2 α -,3 β -,19 α -trihydroxy-urs-12-ene-23,28-dioic acid (Table I), which suggested that the structure of compound **1** should be 2 α -,3 β -,19 α -trihydroxy-urs-12-ene-24,28-dioic acid. The conclusive evidence for the structure of compound **1**




FIGURE 1 The key HMBC and NOE correlations of compound 1.

TABLE 1 ^{13}C -NMR data of 2α -, 3β -, 19α -trihydroxy-urs-12-ene-23,28-dioic acid ($\text{C}_5\text{D}_5\text{N}$) and NMR data of compound 1 ($\text{C}_5\text{D}_5\text{N}$, 500 MHz for ^1H -NMR and 125 MHz for ^{13}C -NMR)

No.	δC	Compound 1			
		δC	DEPT	HMBC	δH
1	48.1	47.9	CH_2	25-H	2.33 dd (3.5, 12.5), $1\beta\text{-H}$
2	68.6	68.2	CH	1-H, 3-H	4.69 m
3	80.9	83.7	CH	1-H, 23-H	3.34 d (9.0)
4	54.7	49.7	C	23-H, 3-H, 5-H	
5	52.2	56.5	CH	1-H, 23-H, 25-H	1.18 m
6	21.4	20.6	CH_2	5-H	
7	33.3	33.4	CH_2	26-H	
8	40.5	39.9	C	15-H, 27-H, 26-H	
9	48.1	46.8	CH	12-H, 25-H, 26-H	1.87 m
10	38.5	38.6	C	1-H, 9-H, 5-H	
11	24.2	23.9	CH_2	12-H	
12	127.7	127.6	CH	18-H	5.51 brs
13	139.9	139.5	C	18-H, 27-H	
14	42.0	41.9	C	12-H, 18-H	
15	29.1	28.9	CH_2	27-H, 16-H	2.23 m, $15\beta\text{-H}$
16	26.3	26.0	CH_2	18-H, 15-H	3.02 m, $16\alpha\text{-H}$
17	48.6	47.9	C	16-H, 18-H	
18	54.7	54.3	CH	12-H, 29-H	2.96 s
19	72.7	72.3	C	18-H, 29-H, 30-H	
20	42.0	42.0	CH	29-H	1.42 m
21	27.1	26.5	CH_2	30-H	
22	38.5	38.1	CH_2		
23	180.6	24.7	CH_3	3-H, 5-H	1.68 s
24	13.4	180.3	C	3-H, 5-H, 23-H	
25	17.3	14.9	CH_3	1-H, 9-H	1.11 s
26	17.1	16.8	CH_3	9-H	1.05 s
27	24.7	24.2	CH_3	15-H	1.65 s
28	180.0	180.5	C	18-H	
29	27.1	26.7	CH_3		1.39 s
30	16.8	16.4	CH_3		1.06 d (6.0)

* 2α -, 3β -, 19α -trihydroxy-urs-12-ene-23,28-dioic acid was numbered as compound 8 in Ref. [2].




FIGURE 2 The structure of compound 3.

was derived from the results of NOESY spectrum which showed cross peaks between 23-H and 3-H, and 23-H and 5-H (Fig. 1). Thus the structure of compound 1 was established as 2 α -,3 β -,19 α -trihydroxy-urs-12-ene-24,28-dioic acid unambiguously.

The structures of compounds 2 and 3 were determined by comparison of the physical and spectral data with those of the Refs. [3–5] and further confirmed by 2D NMR spectra (Fig. 2). Moreover, the ^{13}C -NMR signals of compounds 2 and 3 were assigned totally for the first time on the basis of 2D NMR spectra because of the absence of ^{13}C -NMR data of compound 2 and the incomplete assignment of compound 3 [5].

EXPERIMENTAL SECTION

General Experimental Procedures

Melting points were determined on an X₄ micro-melting point apparatus and were uncorrected. NMR spectra were recorded on a Bruker-AM 500 spectrometer or a INOVA-500 spectrometer. EI-MS were recorded on an AEI MS-50 mass spectrometer and FAB-MS were taken on a ZABspec mass spectrometer. Optical rotation was determined on an AA-IOR Automatic Polarimeter. TLC was performed on silica gel GF₂₅₄ (10–40 μm , Qingdao). Separation and purification were performed by column chromatography on silica gel (200–300 mesh, Qindao) and Sephadex LH-20 (Pharmacia).

Plant Materials

Dried stems of *S. khasianum* were purchased from Xishuangbanna of Yunnan Province in October 1997. A voucher specimen was identified by Prof. H.B. Chen and deposited in the Herbarium of Division of Natural Medicinal Chemistry of Beijing Medical University.

Extraction and Isolation

Air-dried powdered stems of *S. khasianum* (9.5 kg) were percolated with 95% EtOH. After evaporation of the solvent, the residues were suspended in H₂O and then extracted with petroleum ether, ethyl ether and *n*-BuOH, respectively.

The ethyl ether extracts (104 g) were subjected to silica gel column chromatography using CHCl₃-CH₃OH (100:0 to 65:35) as gradient eluting system to afford 91 fractions (500 ml/fraction). Fractions 55–56 were further subjected to silica gel column chromatography eluted with CHCl₃-(CH₃)₂CO (100:0 to 60:40) as gradient solvent system to yield 428 fractions (400 ml/fraction). Fractions 131–140 (600 mg) and fractions 208–250 (1.2 g) were further purified by repeated Sephadex LH-20 and silica gel column chromatography to furnish compound **3** (45 mg) and compound **1** (20 mg) respectively.

The petroleum ether extracts (144 g) were subjected to silica gel column chromatography eluted with petroleum ether-acetone (100:0 to 60:40) as gradient eluting system to yield 321 fractions (500 ml/fraction). Fractions 110–130 (4.5 g) were further chromatographed on silica gel column with petroleum ether-acetyl acetate (95:5) as eluent to afford compound **2** (58 mg).

2α,3β,19α-Trihydroxy-urs-12-ene-24,28-dioic acid (**1**) white powder, m.p. 280–283°C. $[\alpha]_D -45.45$ (in pyridine). FAB-MS m/z 541 ($M^+ + Na$), 519 ($M^+ + 1$). For NMR data see Table I.

3β-Acetoxy-urs-12-ene-11-one (**2**) white needles, m.p. 286–288°C. EI-MS m/z 482 (M^+), 422, 287, 273, 232. ¹H-NMR (CDCl₃, 500 MHz) δ 0.80 (3H, d, $J = 6.0$ Hz, H-29), 0.81, 0.87, 0.88, 1.16, 1.18, 1.29 (each 3H, s, H-28, 23, 24, 26, 25, 27), 0.94 (3H, d, $J = 6.0$ Hz, H-30), 2.04 (3H, s, COCH₃), 2.34 (1H, s, H-9), 2.75 (1H, ddd, $J = 3.5, 3.5, 13.5$ Hz, H-1 β), 4.51 (1H, dd, $J = 4.6, 11.7$ Hz, H-3), 5.54 (1H, s, H-12). ¹³C-NMR (CDCl₃, 125 MHz) δ 38.9 (C-1), 23.6 (C-2), 80.7 (C-3), 38.1 (C-4), 55.1 (C-5), 17.5 (C-6), 32.8 (C-7), 45.2 (C-8), 61.5 (C-9), 36.7 (C-10), 199.5 (C-11), 130.5 (C-12), 164.8 (C-13), 43.7 (C-14), 27.2 (C-15), 27.3 (C-16), 33.9 (C-17), 59.1 (C-18), 39.2 (C-19), 39.3 (C-20), 30.9 (C-21), 40.9 (C-22), 28.1 (C-23), 16.7 (C-24), 16.5 (C-25), 18.6 (C-26), 20.5 (C-27), 28.9 (C-28), 17.5 (C-29), 21.2 (C-30), 21.1 (COCH₃), 170.9 (COCH₃).

Vomifoliol (**3**) white needles, m.p. 108–110°C. EI-MS m/z 206 ($M^+ - H_2O$), 168, 150, 135, 124, 122, 111, 107, 79, 77, 69, 55, 43. ¹H-NMR (CDCl₃, 500 MHz) δ 1.02, 1.08 (each 3H, s, H-11, 12 or H-12, 11), 1.30 (3H, d, $J = 6.5$ Hz, H-10), 1.90 (3H, d, $J = 1.0$ Hz, H-13), 2.19 (1H, brs, OH), 2.24,

2.45 (each 1H, d, $J=17.0$ Hz, H-2), 4.41 (1H, m, H-9), 5.79 (1H, d, $J=15.0$ Hz, H-7), 5.85 (1H, dd, $J=5.0, 15.0$ Hz, H-8), 5.90 (1H, d, $J=1.0$ Hz, H-4). $^{13}\text{C-NMR}$ (CDCl_3 , 125 MHz) δ 41.1 (C-1), 49.6 (C-2), 198.4 (C-3), 128.9 (C-4), 163.4 (C-5), 79.0 (C-6), 126.7 (C-7), 135.7 (C-8), 67.9 (C-9), 23.7 (C-10), 24.0, 22.9 (C-11, 12 or C-12, 11), 19.0 (C-13).

References

- [1] J.D. Lu, H.D. Sun and C.C. Ou. *Acta Pharm. Sinica*, 1963, **10**, 681–682.
- [2] F. Gao, F. Chen, T. Tanaka, R. Kasai, T. Sato and O. Tanaka. *Chem. Pharm. Bull.*, 1985, **33**, 37–40.
- [3] Y.H. Kuo and Y.C. Li. *J. Chin. Chem. Soc.*, 1997, **44**, 321–325.
- [4] C.A.L. Bercht, H.M. Samarah, R.J.J.C. Lousberg, H. Theuns and C.A. Salemink. *Phytochemistry*, 1976, **15**, 830–831.
- [5] R.G. Powell, D. Weisleder and C.R. Smith. *J. Org. Chem.*, 1986, **51**, 1074–1076.